Comparison of antitumor effects of native and recombinant human interferon-α on non-small cell lung cancer cells

Anticancer Research

Volumn 33, Issue 5, 2013, Pages 2043-2046

  Šantak, Goran ^a   Šantak, Maja ^b   Fořćic, Dubravko ^b  

^a Department of Surgery   (Croatia)

^b INSTITUTE OF IMMUNOLOGY   (Croatia)

Author keywords

Apoptosis; Native human interferon alpha; Non small cell lung cancer; p21; Recombinant human interferon alpha; Survivin; Tumor proliferation

Indexed keywords

MESSENGER RNA; PROTEIN P21; RECOMBINANT ALPHA INTERFERON; SURVIVIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; NATIVE HUMAN INTERFERON ALPHA; NON-SMALL CELL LUNG CANCER; P21; RECOMBINANT HUMAN INTERFERON ALPHA; SURVIVIN; TUMOR PROLIFERATION;

ADENOCARCINOMA; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTERFERON-ALPHA; LUNG NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84878191954     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Kirkwood J: Cancer immunotherapy: The interferon-alpha experience. Semin Oncol 29: 18-26, 2002.
2. Grander D, Sangfelt O and Erickson S: How does interferon exert its cell growth inhibitory effect? Eur J Haematol 59: 129-135, 1997. (Pubitemid 27392087)
3. Sangfelt O, Erickson S, Castro J, Heiden T, Einhorn S and Grandér D: Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines. Cell Growth Differ 8: 343-352, 1997. (Pubitemid 27273057)
4. Bekisz J, Baron S, Balinsky C, Morrow A and Zoon KC: Antiproliferative properties of type I and type II interferon. Pharmaceuticals 3: 994-1015, 2010.
5. Mandanas R, Einhorn LH, Wheeler B, Ansari R, Lutz T and Miller ME: Carboplatin (CBDCA) plus alpha interferon in metastatic non-small cell lung cancer. A Hoosier Oncology Group phase II trial. Am J Clin Oncol 16: 519-521, 1993. (Pubitemid 24004105)
6. Kataja V and Yap A: Combination of cisplatin and interferon-alpha 2a (Roferon-A) in patients with non-small cell lung cancer (NSCLC). An open phase II multicentre study. Eur J Cancer 31: 35-40, 1995.
7. Tezuka Y, Endo S, Matsui A, Sato A, Saito K, Semba K, Takahashi M and Murakami T: Potential anti-tumor effect of IFN-λ2 (IL-28A) against human lung cancer cells. Lung Cancer 78: 185-192, 2012.
8. Jonasch E and Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6: 34-55, 2001. (Pubitemid 32155814)
9. Šantak G, Šantak M and Forčić D: Native human IFN-α is amore potent suppressor of HDF response to profibrotic stimuli than recombinant human IFN-α. J Interferon Cytokine Res 27: 481-490, 2007.
10. Šantak G, Šantak M and Forčić D: The role of interleukin-1βand platelet-derived growth factor-AB in antifibrosis mediated by native human interferon alpha. Surgery 148: 490-498, 2010.
11. Židovec S and Mažuran R: Sendai virus induces variouscytokines in human peripheral blood leukocytes: different susceptibility of cytokine molecules to low pH. Cytokine 11: 140-143, 1999.
12. Hobeika AC, Subramaniam PS and Johnson HM: IFN-α inducesthe expression of the cyclin dependent kinase inhibitor p21 in human prostate cancer cells. Oncogene 14: 1165-1170, 1997. (Pubitemid 27141918)
13. Zhou Y, Wang S, Yue BG, Gobl A and Oberg K: Effects of interferon alpha on the expression of p21 cip1/waf1 and cell cycle distribution in carcinoid tumors. Cancer Invest 20: 348-356, 2002. (Pubitemid 34496568)
14. Kameshima H, Tsuruma T, Torigoe T, Takahashi A, Hirohashi Y, Tamura Y, Tsukahara T, Ichimiya S, Kanaseki T, Iwayama Y, Sato N and Hirata K: Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Cancer Sci 102: 1181-1187, 2011.
15. Armstrong MJ, Stang MT, Liu Y, Gao J, Ren B, Zuckerbraun BS, Mahidhara RS, Xing Q, Pizzoferrato E and Yim JH: Interferon Regulatory Factor 1 (IRF-1) induces p21(WAF1/CIP1)-dependent cell cycle arrest and p21(WAF1/CIP1)- independent modulation of survivin in cancer cells. Cancer Lett 319: 56-65, 2012.
16. Carrasco RA, Stamm NB, Marcusson E, Sandusky G, Iversen P and Patel BK: Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer Ther 10: 221-232, 2011.
17. Weiss A, Brill B, Borghouts C, Delis N, Mack L and Groner B: Survivin inhibition by an interacting recombinant peptide, derived from the human ferritin heavy chain, impedes tumor cell growth. J Cancer Res Clin Oncol 138: 1205-1220, 2012.